This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: Journals

New SSC Recommendations and Guidelines Released by JTH

Wednesday, May 6, 2015   (0 Comments)
Posted by: Luke Blount
Share |

The Journal of Thrombosis and Haemostasis (JTH) has accepted the following articles on recommendations from the Scientific and Standardization Committee (SSC) Subcommittees of the ISTH:  

Subcommittee on Platelet Immunology: Recommendations for the use of the non-obese diabetic/severe combined immunodeficiency mouse model in autoimmune and drug-induced thrombocytopenia
Human platelet survival studies have been hampered by the lack of a suitable animal model. Transfusion of human platelets into immunocompetent animals leads to the rapid destruction of these platelets by naturally occurring xenoantibodies. The non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mouse lacks T and B cells, and therefore lack natural antibodies that could destroy infused human platelets. Because of this property, human platelets given to the mouse intravenously circulate for several days, permitting the model to be used for testing the ability of human antibodies to cause platelet destruction in vivo. Preliminary studies have demonstrated the usefulness of the NOD/SCID mouse model for monitoring the survival and immune destruction of human platelets. However, differences exist between the research groups regarding the method of platelet injection, the amount and route of antibody injection, and the preparation of blood samples collected from the animal, making the results poorly comparable. Read more.

Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders: Design of clinical trials for new products in hemophilia
This report presents an alternative approach to the clinical trial design of preauthorization trials for clotting factor products in previously treated patients (PTPs) with severe hemophilia. This approach is rooted in the overall regulatory goals for preregistration product safety and efficacy determination and incorporates both current immunological theories of neoantigenicity and consensus clinical efficacy end point definitions. Read more.

Subcommittee on Haemostasis and Malignancy: Diagnosis and treatment of incidental venous thromboembolism in cancer patients
Modern computed tomography (CT), with its high sensitivity and resolution, has increased the detection of incidental venous thromboembolism (VTE) in the venous and pulmonary vasculature during routine imaging for cancer staging and response assessment. As a result, up to half of all VTEs diagnosed in oncology centers are incidental. Although widely accepted, the diagnosis of incidental VTE is made without using the standard imaging studies required for confirming the presence of symptomatic VTE (i.e. compression ultrasonography for deep vein thrombosis [DVT], and CT pulmonary angiography [CTPA] or ventilation/perfusion lung scan for pulmonary embolism [PE]). The accuracy and reliability of staging imaging in making a diagnosis of DVT or PE have not been established. Read more

Membership Management Software Powered by YourMembership  ::  Legal